| 张龙杰 袁胜利 韩真真 李欢 黄娟.131I-Herceptin 对HER2 过表达乳腺癌细胞Bcl-xL表达的影响[J].现代生物医学进展英文版,2015,15(22):4248-4251. |
| 131I-Herceptin 对HER2 过表达乳腺癌细胞Bcl-xL表达的影响 |
| Effect of 131I-Herceptin on the Expression of Bcl-xL in HER2 OverexpressedBreast Cancer Cells |
| |
| DOI： |
| 中文关键词: 乳腺癌 放射免疫疗法 人表皮生长因子受体2 131I-Herceptin Bcl-xL |
| 英文关键词: Breast cancer Radioimmunotherapy HER2 131I-Herceptin Bcl-xL |
| 基金项目: |
|
| Hits: 643 |
| Download times: 0 |
| 中文摘要: |
| 目的：探讨131I-Herceptin 对HER2 过表达乳腺癌细胞Bcl-xL表达的影响。方法：采用Iodogen 法制备131I-Herceptin，超滤法纯
化后测定其标记率、放射化学纯度和免疫结合率。通过免疫荧光法检测乳腺癌细胞表面HER2 表达水平。131I (4.625 MBq/mL)、
Herceptin (125 ug/mL)及131I-Herceptin (4.625 MBq/mL)干预乳腺癌BT474 细胞后，Western blot检测细胞中Bcl-xL的表达。结果：
131I-Herceptin 的标记率、放射化学纯度和免疫结合率分别为(89.71± 2.93)%、(91.80± 1.43)%和(58.84± 3.35)%。BT474 细胞膜表面
HER2 表达水平明显高于MDA-MB-231 细胞。Herceptin、131I-Herceptin 组BT474 细胞内Bcl-xL表达水平明显低于对照组及131I组
(均P<0.01)，而Herceptin 与131I-Herceptin 组之间细胞内Bcl-xL 含量差异无统计学意义(P>0.05)。结论：131I-Herceptin 保留
Herceptin 对HER2 过表达乳腺癌细胞Bcl-xL表达的抑制作用并促进细胞凋亡，进而与131I 产生协同作用，较Herceptin 更有效地
杀伤HER2 过表达乳腺癌细胞。 |
| 英文摘要: |
| Objective:To explore the effect of 131I-Herceptin on the expression of Bcl-xL in HER2 overexpressed breast cancer
cells.Methods:Herceptin was labeled with 131I using the Iodogen method and 131I-Herceptin was isolated by ultrafiltration membrane, then
the labeling efficiency, radiochemical purity and immunoreactivity were measured. The expression levels of HER2 on the surface of
different breast cancer cells were detected by immunofluorescence. HER2 overexpressed breast cancer cell line BT474 was respectively
treated by normal medium, 131I (4.625 MBq/mL), Herceptin (125 ug/mL) and 131I-Herceptin (4.625 MBq/mL), then the expression of
Bcl-xL were detected by Western blot analysis.Results:The labeling efficiency, radiochemical purity and immunoreactivity of
131I-Herceptin were (89.71± 2.93)%, (91.80± 1.43)% and (58.84± 3.35)% respectively. The immunofluorescence indicated that the
expression level of HER2 in BT474 cells was significantly higher than that of MDA-MB-231 cells. The Bcl-xL expressions of both
Herceptin and 131I-Herceptin groups were much lower than those of control and 131I groups (all P<0.01), while there was no significant
difference of Bcl-xL expression between Herceptin and 131I-Herceptin (P>0.05).Conclusion:131I-Herceptin enhances apoptosis by
retaining the effect of Herceptin on down-regulation Bcl-xL, thus can exert synergistic effects with 131I and kill HER2 overexpressed
breast cancer cells more effectively than Herceptin. |
|
View Full Text
View/Add Comment Download reader |
| Close |
